Janice N. Tieu

Array ( [id] => 11381519 [patent_doc_number] => 20170007575 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-12 [patent_title] => 'Ready to Use Ketorolac Formulations' [patent_app_type] => utility [patent_app_number] => 15/211560 [patent_app_country] => US [patent_app_date] => 2016-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 7932 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15211560 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11381559 [patent_doc_number] => 20170007614 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-12 [patent_title] => 'Autotaxin inhibitors' [patent_app_type] => utility [patent_app_number] => 15/210560 [patent_app_country] => US [patent_app_date] => 2016-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49618 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15210560 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11113526 [patent_doc_number] => 20160310499 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-27 [patent_title] => 'Highly Active Anti-Neoplastic and Anti-Proliferative Agents' [patent_app_type] => utility [patent_app_number] => 15/201286 [patent_app_country] => US [patent_app_date] => 2016-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 37541 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15201286 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12198509 [patent_doc_number] => 09901556 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-02-27 [patent_title] => 'Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders' [patent_app_type] => utility [patent_app_number] => 15/184262 [patent_app_country] => US [patent_app_date] => 2016-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 2710 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 214 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15184262 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12842617 [patent_doc_number] => 20180172712 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-21 [patent_title] => METHODS AND MATERIALS FOR ASSESSING HYDROGEN PEROXIDE ACCUMULATION IN CELLS [patent_app_type] => utility [patent_app_number] => 15/737219 [patent_app_country] => US [patent_app_date] => 2016-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11053 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15737219 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11393838 [patent_doc_number] => 20170014373 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-19 [patent_title] => 'METHODS OF TREATING CANCER' [patent_app_type] => utility [patent_app_number] => 15/183636 [patent_app_country] => US [patent_app_date] => 2016-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45060 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15183636 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11127902 [patent_doc_number] => 20160324878 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-10 [patent_title] => 'PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASES' [patent_app_type] => utility [patent_app_number] => 15/183340 [patent_app_country] => US [patent_app_date] => 2016-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 21426 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15183340 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12831733 [patent_doc_number] => 20180169083 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-21 [patent_title] => INHIBITORS OF NUCLEOTIDYL TRANSFERASES AND USE IN HERPES AND HEPATITIS VIRAL INFECTIONS THEREFOR [patent_app_type] => utility [patent_app_number] => 15/735197 [patent_app_country] => US [patent_app_date] => 2016-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19809 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -55 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15735197 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11335527 [patent_doc_number] => 20160361282 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-15 [patent_title] => 'ADMINISTRATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS' [patent_app_type] => utility [patent_app_number] => 15/175188 [patent_app_country] => US [patent_app_date] => 2016-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 2686 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15175188 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11348825 [patent_doc_number] => 20160367565 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-22 [patent_title] => 'DEVICES AND METHODS OF TREATING METHAMPHETAMINE ADDICTION AND MEDICAL AND BEHAVIORAL CONSEQUENCES OF METHAMPHETAMINE USE AND OF HIV INFECTION' [patent_app_type] => utility [patent_app_number] => 15/175284 [patent_app_country] => US [patent_app_date] => 2016-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 12419 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15175284 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11362820 [patent_doc_number] => 20170000801 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-05 [patent_title] => 'TRIARYLMETHANE ANALOGS AND THEIR USE IN TREATING CANCERS' [patent_app_type] => utility [patent_app_number] => 15/173946 [patent_app_country] => US [patent_app_date] => 2016-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 18575 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15173946 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11075662 [patent_doc_number] => 20160272625 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-22 [patent_title] => 'HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF' [patent_app_type] => utility [patent_app_number] => 15/169799 [patent_app_country] => US [patent_app_date] => 2016-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32128 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15169799 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11310169 [patent_doc_number] => 20160346279 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-01 [patent_title] => 'Histone Deacetylase 6 Selective Inhibitors for the Treatment of Cisplatin-Induced Peripheral Neuropathy' [patent_app_type] => utility [patent_app_number] => 15/170335 [patent_app_country] => US [patent_app_date] => 2016-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 14866 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15170335 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12786157 [patent_doc_number] => 20180153888 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-07 [patent_title] => COMBINATION THERAPY WITH AXL INHIBITOR AND IMMUNE CHECKPOINT MODULATOR OR ONCOLYTIC VIRUS [patent_app_type] => utility [patent_app_number] => 15/577804 [patent_app_country] => US [patent_app_date] => 2016-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27469 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15577804 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13051341 [patent_doc_number] => 10047051 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-14 [patent_title] => Substituted pyridines and method of use [patent_app_type] => utility [patent_app_number] => 15/164317 [patent_app_country] => US [patent_app_date] => 2016-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62791 [patent_no_of_claims] => 47 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15164317 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12675679 [patent_doc_number] => 20180117059 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-03 [patent_title] => METHODS FOR TREATING EGFR MUTANT CANCERS [patent_app_type] => utility [patent_app_number] => 15/574347 [patent_app_country] => US [patent_app_date] => 2016-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8980 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15574347 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11059505 [patent_doc_number] => 20160256467 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-08 [patent_title] => 'ANTI-PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (ANTI-PCSK9) COMPOUNDS AND METHODS OF USING THE SAME IN THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES' [patent_app_type] => utility [patent_app_number] => 15/152703 [patent_app_country] => US [patent_app_date] => 2016-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 9865 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15152703 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12724183 [patent_doc_number] => 20180133228 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-17 [patent_title] => Human papilloma virus replication inhibitors [patent_app_type] => utility [patent_app_number] => 15/573362 [patent_app_country] => US [patent_app_date] => 2016-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8854 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15573362 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12701950 [patent_doc_number] => 20180125816 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-10 [patent_title] => SAROGLITAZAR MAGNESIUM FOR THE TREATMENT OF CHYLOMICRONEMIA SYNDROME [patent_app_type] => utility [patent_app_number] => 15/572538 [patent_app_country] => US [patent_app_date] => 2016-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4607 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15572538 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11046165 [patent_doc_number] => 20160243124 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-25 [patent_title] => 'METHOD FOR TREATING ACUTE MYELOID LEUKEMIA' [patent_app_type] => utility [patent_app_number] => 15/147037 [patent_app_country] => US [patent_app_date] => 2016-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4096 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15147037 [rel_patent_id] =>[rel_patent_doc_number] =>)